Objective: To determine if primary transpupillary thermotherapy can achieve local remission of choroidal melanoma. Secondary objectives were to determine safety of treatment, visual acuity and evaluate complications. The long term objective was to evaluate the impact of treatment on survival without metastatic disease.
Methods And Patients: Thirty-one patients with small choroidal melanomas were treated with transpupillary thermotherapy between 1st December 1997 and 15th June 2001. These patients satisfied predetermined inclusion criteria. To perform the treatment, an infrared diode laser (810 nm) with emission adapted for use with a surgical microscope was used, applying the treatment through a Mainster contact lens. In most patients, the diameter of the irradiation beam was 2 mm, the exposure time was 1 minute and the level of energy given was between 250 and 800 mW.
Results: Of 31 patients treated, 26 patients were evaluated in this study. With a mean follow-up of 23.13 months (standard deviation (S.D.): 15 and median: 18.6 months), tumoral remission was observed in 50% of the evaluated tumors. The post-treatment visual acuity in the patients with tumoral remission was better than in patients with treatment failure (P = 0.004).
Conclusions: Primary treatment of choroidal melanomas with transpupillary thermotherapy may be a good therapeutic option in selected cases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4321/s0365-66912005000300008 | DOI Listing |
Surv Ophthalmol
January 2025
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China; Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address:
Because of its benign nature and rarity, circumscribed choroidal hemangioma (CCH) often receives limited attention, leading to a high rate of misdiagnosis and a lack of standardized treatment protocols. We provide a thorough clarification of the demographics, clinical features, diagnosis, management, and prognosis of CCH. We conducted a systematic search of the PubMed, EMBASE, and Ovid databases up to December, 2023, to identify relevant studies.
View Article and Find Full Text PDFCan J Ophthalmol
January 2025
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the clinical and prognostic features of uveal metastasis in a Chinese population and compare these features across different primary cancers.
Design: Retrospective cross-sectional study.
Participants: 161 patients with uveal metastasis at Beijing Tongren Hospital.
Cureus
December 2024
Department of Ophthalmology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, CHN.
Choroidal nevus is the most common intraocular tumor, and most cases are benign and have no symptoms. However, choroidal nevus carries a low risk for transformation into melanoma, which is a highly aggressive and deadly cancer. In this case report, we present a male patient with blurred vision in his left eye for six months.
View Article and Find Full Text PDFRetina
November 2024
Anant Bajaj Retina Institute, LV Prasad Eye Institute, Hyderabad, India.
Int Ophthalmol
July 2024
Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey.
Purpose: To review long-term outcomes of circumscribed choroidal hemangioma (CCH).
Methods: Hospital charts of all CCH cases diagnosed from 2008 to 2019 were retrospectively reviewed.
Results: All 172 patients were managed with either observation, transpupillary thermotherapy, argon laser photocoagulation, photodynamic therapy, plaque brachytherapy or stereotactic radiosurgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!